Atypical Stevens–Johnson syndrome caused by pembrolizumab in the treatment of metastatic melanoma – Are corticosteroids a safe treatment option?
Pembrolizumab is a humanized monoclonal antibody that targets programmed cell death receptor-1. Stevens–Johnson syndrome (SJS) secondary to pembrolizumab has rarely been described in the treatment of malignant melanoma (MM). A 62-year-old woman developed a widespread bullous eruption following admin...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wolters Kluwer Medknow Publications
2020-01-01
|
| Serie: | Journal of Dermatology and Dermatologic Surgery |
| Soggetti: | |
| Accesso online: | http://www.jddsjournal.org/article.asp?issn=2352-2410;year=2020;volume=24;issue=2;spage=137;epage=139;aulast=O'Connor |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|